NLS Pharma Announces Phase 2 Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And ... - PR Newswire (press release)

NLS Pharma Announces Phase 2 Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And ...PR Newswire (press release)STANS, Switzerland, May 16, 2017 /PRNewswire/ -- NLS Pharma Group (NLS Pharma), a Swiss biotech group focusing on the development of novel treatments for ADHD, sleep disorders, and cognitive impairments, announced today that its "Double-Blind ...